Adalat

Anal sphincter hypertonia, Proctalgia, Altitude Sickness + 12 more

Treatment

3 FDA approvals

20 Active Studies for Adalat

What is Adalat

Nifedipine

The Generic name of this drug

Treatment Summary

Nifedipine (brand name BAY a 1040) is a type of medication used to treat high blood pressure. It belongs to a class of drugs known as calcium channel blockers and is the first of its kind to be developed. Nifedipine works by blocking calcium from entering the cells in the walls of arteries, which reduces tension and widens them. This helps to lower blood pressure and improve blood flow. There are newer, second and third generation versions of nifedipine with slower onset times and longer-lasting effects, such as amlodipine. Nifedipine was approved by

Procardia

is the brand name

image of different drug pills on a surface

Adalat Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Procardia

Nifedipine

1981

355

Approved as Treatment by the FDA

Nifedipine, otherwise called Procardia, is approved by the FDA for 3 uses like Angina, Stable and Failed conventional therapy .

Angina, Stable

Helps manage Chronic Stable Angina Pectoris

Failed conventional therapy

Helps manage Failed conventional therapy

Vasospastic Angina

Helps manage Vasospastic Angina

Effectiveness

How Adalat Affects Patients

Nifedipine is a medication that helps to lower blood pressure and increase the amount of oxygen that reaches the heart. It needs to be taken three times a day, typically in doses of 10 to 120mg daily. It is important for patients to be aware of the risks associated with taking this medication, such as excessively low blood pressure, chest pain and heart attack.

How Adalat works in the body

Nifedipine helps reduce blood pressure and ease chest pain by blocking the entry of calcium ions into cells. This stops the cells from becoming over-stimulated, allowing blood vessels to relax and provide more oxygen to the heart.

When to interrupt dosage

The suggested dose of Adalat is contingent upon the diagnosed condition, including Achalasia, Ureteral Calculus and Hypertensive disease. The amount of dosage varies, as per the method of delivery (e.g. Tablet, film coated, extended release or Capsule) specified in the table below.

Condition

Dosage

Administration

Proctalgia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Vasospastic Angina

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Edema

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Ureteral Calculi

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Angina, Stable

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Fissure in Ano

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Failed conventional therapy

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Altitude Sickness

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Raynaud Disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive disease

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Hypertensive Emergency

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Anal sphincter hypertonia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Obstetric Labor, Premature

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Esophageal Achalasia

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Pulmonary Hypertension

30.0 mg, 60.0 mg, 90.0 mg, , 10.0 mg, 20.0 mg, 5.0 mg, 20.0 mg/mL

Tablet, film coated, extended release, Oral, , Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, extended release - Oral, Tablet, extended release, Capsule - Oral, Capsule, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Kit; Tablet, delayed release; Tablet, extended release - Oral, Kit; Tablet, delayed release; Tablet, extended release

Warnings

Adalat has one contraindication, thus its use should be avoided if any of the situations in the table below are present.

Adalat Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Nifedipine may interact with Pulse Frequency

There are 20 known major drug interactions with Adalat.

Common Adalat Drug Interactions

Drug Name

Risk Level

Description

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Nifedipine.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Nifedipine.

Anagrelide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Anagrelide.

Arsenic trioxide

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Arsenic trioxide.

Artemether

Major

The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Artemether.

Adalat Toxicity & Overdose Risk

The lowest toxic dose of the drug in rats was found to be 1022mg/kg and in mice was 202mg/kg. An overdose on this drug may cause low blood pressure, problems with the heart rate, and rapid heartbeat. Treatment for an overdose should involve monitoring vital signs, raising the patient's extremities, and administering fluids, vasopressors, and calcium.

image of a doctor in a lab doing drug, clinical research

Adalat Novel Uses: Which Conditions Have a Clinical Trial Featuring Adalat?

101 active investigations are exploring the potential of Adalat to mitigate Achalasia, Hypertensive Emergency and Anal Fissures.

Condition

Clinical Trials

Trial Phases

Pulmonary Edema

0 Actively Recruiting

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

Obstetric Labor, Premature

2 Actively Recruiting

Not Applicable

Angina, Stable

0 Actively Recruiting

Esophageal Achalasia

0 Actively Recruiting

Altitude Sickness

3 Actively Recruiting

Phase 1, Phase 2, Early Phase 1, Not Applicable

Raynaud Disease

1 Actively Recruiting

Phase 4

Pulmonary Hypertension

36 Actively Recruiting

Phase 2, Phase 3, Phase 1, Not Applicable, Early Phase 1

Proctalgia

0 Actively Recruiting

Hypertensive Emergency

1 Actively Recruiting

Phase 2

Fissure in Ano

0 Actively Recruiting

Vasospastic Angina

1 Actively Recruiting

Phase 2, Phase 3

Anal sphincter hypertonia

0 Actively Recruiting

Ureteral Calculi

0 Actively Recruiting

Failed conventional therapy

0 Actively Recruiting

Adalat Reviews: What are patients saying about Adalat?

5

Patient Review

11/13/2007

Adalat for Angina

3

Patient Review

1/16/2008

Adalat for Angina

My blood pressure and chest pain are much more manageable now.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about adalat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is nifedipine and Adalat the same thing?

"Nifedipine is available as an oral tablet in the brand-name drugs Adalat CC, Afeditab CR, and Procardia XL. These are all extended-release tablets, meaning the drug is slowly released into your bloodstream over time."

Answered by AI

When do you give Adalat?

"It is recommended that you take Adalat CC once a day on an empty stomach. Adalat CC is an extended release dosage form, which means you should swallow the tablet whole, without biting or dividing it. In general, you should start with 30 mg once a day, and increase the dosage over a 7-14 day period."

Answered by AI

Is Adalat for blood pressure?

"Nifedipine, sold under the brand name Adalat, is a calcium channel blocker used to lower high blood pressure and treat chest pain. Nifedipine slows the movement of calcium into the cells of the heart and blood vessels. This relaxes the blood vessels, lowers blood pressure, and makes it easier for the heart to pump."

Answered by AI

What is Adalat used for?

"This medication prevents certain types of chest pain by blocking calcium channels. This allows the individual to exercise more and have fewer angina attacks."

Answered by AI

Clinical Trials for Adalat

Image of Caridad Center, Inc. in Boynton Beach, United States.

CHW Nutrition Support for Type 2 Diabetes

18+
All Sexes
Boynton Beach, FL

This study tests whether adding CHW support to usual nutrition care helps adults with type 2 diabetes, hypertension, or chronic kidney disease manage their diet and health. At Caridad Center, a free clinic in Palm Beach County, Florida, usual care includes medical nutrition therapy from a registered dietitian and medically tailored groceries. Many patients find it hard to keep up dietary changes because of limited nutrition knowledge, cooking skills, food costs, and cultural fit. Two hundred adults will be randomly assigned to usual care or usual care plus INTEGRATE-CHW, a 12-week program of six sessions with a trained CHW. In each session the participant selects one or two goals from the dietitian's plan and builds an action plan with the CHW. The dietitian remains responsible for the nutrition plan. The study will compare nutrition self-efficacy, nutrition literacy, diet quality, food security, and clinical measures between groups at baseline and Week 12. It will also evaluate how well the program fits into routine clinic care.

Waitlist Available
Has No Placebo

Caridad Center, Inc.

Janet Diaz Martinez

Image of Satellite Healthcare - Daly City in San Francisco, United States.

Blood Pressure Management for Kidney Failure

18+
All Sexes
San Francisco, CA

The GOAL-BP pilot study will help determine whether a study comparing two blood pressure goals can be carried out in adults with end-stage kidney disease and high blood pressure who receive peritoneal dialysis. The main questions it aims to answer are whether eligible patients can be recruited for the study. Researchers will compare two goals for the top blood pressure number (systolic blood pressure): below 120 mmHg versus below 140 mmHg.This pilot study will help plan a larger trial in the future. Participants will: * Be assigned by chance to one of the two blood pressure goals. * Have their blood pressure measured at clinic visits about every two weeks. * Work with their kidney doctor on recommended changes to fluid management, peritoneal dialysis treatment, or blood pressure medicines to reach their assigned goal. * Be part of the study for about four and a half months.

Recruiting
Has No Placebo

Satellite Healthcare - Daly City (+2 Sites)

Chi-yuan Hsu, MD, MS

Image of Huntsman Cancer Institute, University of Utah in Salt Lake City, United States.

Belzutifan for Polycythemia

18+
All Sexes
Salt Lake City, UT

Some people develop erythrocytosis, a condition characterized by having too many red blood cells, because of inherited changes (mutations) in genes such as EPAS1, EGLN1, or VHL. These genes are involved in the body's oxygen-sensing pathway and can cause the body to produce excess red blood cells. High red blood cell counts can increase the risk of symptoms and complications, including headaches, blood clots, and cardiovascular problems. This study will evaluate whether belzutifan, a medication that blocks the activity of HIF-2α, can reduce red blood cell production and improve blood counts in patients with erythrocytosis caused by these genetic mutations. Participants will receive belzutifan and undergo regular clinical assessments and laboratory testing to monitor treatment response and safety. The results of this study may provide a new targeted treatment option for patients with hereditary erythrocytosis caused by abnormalities in the oxygen-sensing pathway.

Phase 2
Waitlist Available

Huntsman Cancer Institute, University of Utah

Josef T. Prchal, MD

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Have you considered Adalat clinical trials?

We made a collection of clinical trials featuring Adalat, we think they might fit your search criteria.
Go to Trials
Image of Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington in Arlington, United States.

Alcohol Abstinence for High Blood Pressure

26 - 49
All Sexes
Arlington, TX

The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high blood pressure. High blood pressure is a major risk factor for cardiovascular disease (CVD), including heart attack and stroke. In this randomized, controlled trial, men and women aged 26 to 49 years who regularly consume alcohol and have high blood pressure will be assigned by chance to either stop drinking alcohol or continue their usual drinking habits for 8 weeks. Researchers will compare changes in blood pressure and other cardiovascular disease risk factors between the two groups. The information gained from this study may help researchers and health care providers better understand the effects of alcohol consumption on cardiovascular health and whether alcohol abstinence can reduce heart disease risk, especially in adults with high blood pressure.

Recruiting
Has No Placebo

Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington

Image of Department of Family & Community Medicine; University of Alabama at Birmingham in Birmingham, United States.

Treatment for High Blood Pressure

18+
All Sexes
Birmingham, AL

The researchers will invite 30 patients in primary care who have high blood pressure to participate in this health program with a supportive partner of their choosing (these will be the "participant pairs"). Participant pairs will be invited to complete the Heart Care Pairs health program that will include up to six sessions each including 1) some education on a health habit like physical activity and heart healthy foods, 2) goal setting together, and 3) talk about healthy communication to support one another with heart healthy habits. The researchers will work with participants to address things that get in the way of coming for visits like offering transportation and offering telehealth visits. The researchers are seeing how this program works in real life so participants will be asked to complete as many sessions as they want to and can attend. The researchers will be interested in what participants think about the sessions, if they were satisfied with the visits, and if they would recommend the program to others in their community. The researchers will ask these questions in interviews with participants. The researchers will also ask up to 25 primary care workers about how they view the program as helpful to their work with patients with high blood pressure and whether they would refer more patients to the program in the future.

Waitlist Available
Has No Placebo

Department of Family & Community Medicine; University of Alabama at Birmingham

Have you considered Adalat clinical trials?

We made a collection of clinical trials featuring Adalat, we think they might fit your search criteria.
Go to Trials
Image of University of Ottawa in Ottawa, Canada.

Heat and Hypoxia for Occupational Stress

18 - 70
Male
Ottawa, Canada

Extreme heat events are becoming more frequent, intense, and prolonged, increasing the risk of heat-related illness among workers performing physically demanding work in hot environments. Occupational heat-stress guidelines use work-rest schedules to limit increases in core temperature and physiological strain, but they do not clearly define the safe maximum duration of continuous work before heat-mitigation controls should begin, known as the initial stay time. Recent work has generated initial stay time recommendations for young and older workers performing moderate-intensity work in the heat; however, these recommendations were developed under normoxic conditions. In many workplaces, heat may occur alongside additional stressors such as hypoxia, including work at altitude or in oxygen-reduced environments. Hypoxia can increase cardiovascular strain, reduce arterial oxygen saturation, and impair exercise tolerance, potentially compromising heat-stress guidance developed under normal oxygen conditions. Older workers may be especially vulnerable because of age-related reductions in thermoregulatory and cardiovascular function. It remains unclear whether hypoxia increases physiological strain during work in the heat or whether current initial stay time and recovery recommendations remain protective under combined heat and hypoxic stress. The primary objective of this study is to determine whether hypoxia increases physiological strain during moderate-intensity work in the heat in young and older males. Specifically, the study will assess whether normoxia-derived initial stay times and recovery recommendations for work at 29°C wet-bulb globe temperature (37.5°C, 35% RH) remain effective during exposure to 14% inspired oxygen, simulating approximately 3000 m altitude. Healthy young and older males will complete two simulated occupational heat exposures: heat alone and heat plus hypoxia. Participants will perform moderate-intensity treadmill work based on age-specific initial stay times, followed by prescribed work-rest cycles and seated recovery. Core temperature, cardiovascular strain, oxygen saturation, skin temperature, hydration status, perceptual responses, mood, environmental stress symptoms, and cognitive function will be assessed to determine whether hypoxia modifies responses to work in the heat. Findings will help determine whether occupational heat-stress guidance requires refinement for workers exposed to combined heat and hypoxic stress.

Recruiting
Has No Placebo

University of Ottawa

Glen P Kenny, PhD

Image of NeuroFit Lab, Ivor Wynne Centre, McMaster University in Hamilton, Canada.

Isometric Handgrip Exercise for High Blood Pressure

65+
All Sexes
Hamilton, Canada

The goal of this clinical trial is to evaluate whether a short, supervised isometric handgrip exercise program is feasible and acceptable for older adults with elevated blood pressure or hypertension. It will also explore whether this type of exercise may improve blood pressure and cognitive function. The main questions it aims to answer are: * Is this handgrip exercise program practical and acceptable for older adults to participate in within a community exercise setting? * Does participation in the program lead to changes in blood pressure and cognitive function? Researchers will compare two handgrip devices to determine whether the method of delivering the exercise influences feasibility and outcomes. Participants will: * Be randomly assigned to use one of two handgrip devices. * Complete supervised exercise sessions twice per week for 4 weeks. * Perform brief handgrip contractions at a set intensity during each session. * Complete blood pressure and cognitive assessments before and after the program.

Recruiting
Has No Placebo

NeuroFit Lab, Ivor Wynne Centre, McMaster University (+1 Sites)

Jennifer Heisz, PhD

Image of Vanderbilt University Medical Center in Nashville, United States.

2-HOBA for Salt Sensitivity of Blood Pressure

18+
All Sexes
Nashville, TN

Hypertension is the leading cause of preventable deaths globally, driven by complications such as myocardial infarction, stroke, heart failure, and kidney disease. Recent updates in hypertension classification by the American Heart Association (AHA) place nearly half of the U.S. population in the hypertensive category. Excess dietary salt is a major risk factor for hypertension, with 50% of hypertensive individuals exhibiting salt-sensitivity of blood pressure (SSBP). SSBP is an independent predictor of cardiovascular events and death. While kidney mechanisms in salt-sensing have been extensively studied, emerging evidence suggests that immune cells can also sense sodium (Na+). This trial hypothesizes that myeloid cell-derived isolevuglandins (IsoLGs) drive endothelial dysfunction, perpetuating the salt-sensitive phenotype. Preliminary data indicate that targeting IsoLGs with the IsoLG scavenger 2-hydroxybenzylamine (2-HOBA) may interrupt this immune-vascular axis, reducing salt sensitivity and associated cardiovascular risks. This phase 2 clinical trial aims to investigate the role of 2-HOBA in modulating immune cell function within blood vessels in hypertensive patients. The study will explore the impact of immunity on salt sensitivity and assess 2-HOBA's potential to reduce endothelial dysfunction, improve immune cell activation, and alleviate SSBP.

Phase 2
Recruiting

Vanderbilt University Medical Center

Have you considered Adalat clinical trials?

We made a collection of clinical trials featuring Adalat, we think they might fit your search criteria.
Go to Trials